Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: September 10, 2018
Subject: Announcement of results from an indirect treatment comparison of Nucala (mepolizumab) versus benralizumab and reslizumab for severe eosinophilic asthma, published in The Journal of Allergy and Clinical Immunology.
Key Financial Metrics
This filing is a scientific and clinical announcement. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on clinical trial data and product efficacy.
Material Changes and Clinical Results
The filing details a robust indirect treatment comparison (ITC) involving data from 11 separate studies. Key findings regarding Nucala (mepolizumab) compared to competitors include:
- Exacerbation Reduction: Nucala significantly reduced clinically significant exacerbations compared to both benralizumab and reslizumab across all eosinophil levels in adjusted analysis.
- Comparison to Benralizumab: Reduction in exacerbations ranged from 34% to 45% across subgroups (eosinophil counts ≥150, ≥300, and ≥400 cells/µL).
- Comparison to Reslizumab: Reduction in exacerbations was 45% in the ≥400 cells/µL subgroup.
- Asthma Control: Nucala demonstrated significantly greater improvements in asthma control (ACQ score) compared to both competitors.
- Lung Function: No significant differences were found between Nucala and the competitors regarding lung function (FEV1) or reductions in exacerbations requiring emergency room visits/hospitalization.
Outlook, Risks, and Contingencies
Management Commentary: The study aims to inform clinical decision-making by evaluating the relative efficacy of anti-IL5 pathway treatments based on blood eosinophil counts. Nucala is positioned as the leading biologic in this indication and the only anti-IL5 therapy approved for pediatric use (ages 6-17) in Europe.
Risks and Safety Information:
- Contraindications: Hypersensitivity to mepolizumab; not for acute asthma exacerbations.
- Adverse Events: Common reactions include headache, injection site reactions, and back pain. Serious risks include hypersensitivity reactions (anaphylaxis), herpes zoster, and potential complications with helminth infections.
- Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the commercial impact of the clinical superiority claims on Nucala's market share against benralizumab and reslizumab.
- Review the full publication in The Journal of Allergy and Clinical Immunology for detailed methodology and limitations of the indirect treatment comparison.
- Monitor regulatory updates regarding Nucala's approval status in key markets (US, Europe, Japan, Canada) for indications beyond severe eosinophilic asthma (e.g., EGPA, nasal polyposis).
- Assess the safety profile data regarding injection site reactions and hypersensitivity in the context of long-term patient adherence.